A trial of dapagliflozin for kidney protection in type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests if dapagliflozin (a medication for diabetes and kidney health) can help prevent kidney injury in people with type 1 diabetes. It is for adults aged 18 to 64 who have moderately reduced kidney function and some protein in their urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 64 years old.
- You must have type 1 diabetes for at least 6 months.
- Your body mass index (BMI) must be 21 or higher.
- Your kidney function (eGFR) must be between 30 and 90, and you must have some protein in your urine (UACR between 50 and 3000).
- You must be willing to manage your own insulin therapy and check your blood sugar regularly.
- You cannot have had severe low blood sugar (coma/seizure) or diabetic ketoacidosis recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
This study tests whether a medication called dapagliflozin (a type of SGLT2 inhibitor) can be used safely in people with type 1 diabetes by checking blood ketone levels. It may help find a way to lower the risk of a serious condition called ketoacidosis while using this medication.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
This study tests if a once-daily medication called dapagliflozin (Forxiga) can reduce inflammation and improve iron use and red blood cell production in people with both type 2 diabetes and chronic kidney disease. It may help protect your kidneys and overall health.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This trial tests whether the diabetes drug dapagliflozin can help people with pulmonary hypertension (high blood pressure in the lungs). The goal is to see if it improves symptoms and heart function.
Hear when a new Type 1 Diabetes Mellitus With Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.